19
total announcements
EPIGRAL.NS · 15 min delayed
Epigral Limited
Epigral Limited has informed the Exchange about an Investor / Analyst Plant Visit on Thursday, 03.09.2026, at Dahej, Gujarat, as part of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Epigral Limited
Epigral Limited has informed the Exchange about a One-on-One Meeting with Investor/Analyst on Thursday, 20th August 2026, at Ahmedabad. The meeting is subject to change due to exigencies. The latest Earnings Presentation and Corporate Presentation are available on the company's website.
Epigral Limited
Epigral Limited has informed the Exchange about participation in EMKAY Confluence 2026 on 12th August, 2026.
Epigral Limited
Epigral Limited has informed the Exchange about a One-on-One Meeting with Investor / Analyst on Monday, 3rd August, 2026.
Epigral Limited
Epigral Limited has released the transcript of its Q1 FY27 earnings conference call, discussing its performance in a challenging operating environment. The company reported a 15% revenue growth and 25% EBITDA margin, driven by increased sales volume and improved realization. Epigral also announced a strategic capex plan for two new projects, including a 125,000 tons per annum Epoxy Resin & Formulations plant and a multipurpose plant.
Epigral Limited
Epigral Limited has published un-audited financial results for the first quarter ended June 30, 2026, in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Epigral Limited
Epigral Limited has informed the Exchange about the link of recording of a conference call discussing Q1 FY27 results, available at https://epigral.com/wp-content/uploads/2026/07/10045461.mp3 and https://epigral.com/results/
Epigral Limited
Epigral Limited has released its Q1FY27 investor presentation, highlighting a 15% revenue growth and 25% EBITDA margin, despite macroeconomic volatility. The company has approved strategic investments in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP) to drive future diversified growth.
Epigral Limited
Epigral Limited has announced its Q1FY27 financial results, with a 25% jump in PAT to ₹ 99 Cr, and a 15% rise in revenue to ₹ 709 Cr. The company is also planning to invest ₹600 Cr in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP).
Epigral Limited
Epigral Limited has announced the adoption of a new line of business, establishing a new manufacturing facility for Epoxy Resin & Formulations and Multi-Purpose Plant at its existing facility in Dahej, Gujarat, with a proposed capacity of 1,25,000 TPA and an estimated investment of Rs. 600 Cr.
Epigral Limited
Epigral Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, showing a profit before tax of ₹133.18 crore and a profit after tax of ₹99.18 crore. The company's revenue from operations was ₹705.36 crore, and its expenses were ₹576.28 crore. The results were approved by the Board of Directors on July 27, 2026.
Epigral Limited
Epigral Limited has informed the Exchange about Conference Call on Monday, 27th July, 2026 to discuss Q1 FY27 Results.
Epigral Limited
Epigral Limited has responded to a query from the National Stock Exchange of India Limited regarding a significant increase in trading volume. The company assured that it has made all necessary disclosures as per SEBI regulations and is not connected with the movement in volume or price.
Epigral Limited
Epigral Limited has observed a significant increase in volume, prompting the NSE to write to the company for a response, ensuring investors have the latest information and safeguarding their interests.
Epigral Limited
Epigral Limited has informed the Exchange about Credit Rating- Revision, with CRISIL Ratings assigning revised ratings to the Company's bank facilities.
Epigral Limited
Epigral Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming securities received for dematerialisation during the quarter ended 30th June 2026.
Epigral Limited
Epigral Limited has informed the Exchange about the incorporation of a wholly-owned subsidiary, Epigral Advanced Materials Limited, with a paid-up capital of Rs. 1,00,000 and 10,000 equity shares of Rs. 10 each.
Epigral Limited
Epigral Limited has submitted a disclosure under SEBI Takeover Regulations, indicating a potential takeover or acquisition.
Epigral Limited
Epigral Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will remain closed for all Insiders, Directors, Promoters, Designated Persons, and their Immediate Relatives from 1st July, 2026, till the expiry of 48 hours after the declaration of the Un-Audited Financial Results for the First Quarter ended 30th June, 2026.